The General Medical Council (GMC) good practice prescribing guidance states 'At each review, you should confirm that the patient is taking their medicines as directed, and check that the medicines are still needed, effective and tolerated' (GMC, 2013) . Medication reviews are an important part of the repeat prescribing process.
In comparison with long-term condition reviews, a medication review looks at all the patient's medication and conditions as a whole. In many patients this review happens yearly and, once completed, medication is authorised for a further year. Therefore, anything missed at the review is likely to continue for at least another year. However, ensuring that all the requirements of a medication review are met is a difficult task and will often uncover many areas that require addressing. This can create time pressures within the usual 10-minute consultation. Nevertheless, a practice that has a robust system in place for medication reviews can have more confidence that when signing repeat prescriptions these are free of clinically important errors (Avery et al., 2012) . 
Case study 1. Mrs Peterson.
Mrs Peterson is a 65-year-old lady who has come to see you for her annual medication review. She has no concerns about her tablets and says she always remembers to take them. Mrs Peterson has attended for her annual hypertension review last month, her weight is 65 kg, height is 165 cm and her blood pressure and recent blood tests (erythrocyte sedimentation rate, urea and electrolytes, and lipids) are all normal.
Her medical history includes:
. Polymyalgia rheumatica which started 6 months ago . Depression for which she has had treatment for 18 months . Hypertension and coronary heart disease primary prevention which had been coded for 6 years Her family history includes a maternal hip fracture at 73 years old. Mrs Peterson's current repeat medications are shown in Fig. 1 . Reflect on the medication. How many issues can you identify? Are there any changes to the medication you would consider?
Comments: Aspirin is no longer recommended in primary prevention and therefore a discussion could be had with the patient about stopping aspirin and reducing her risk of gastric bleeding. Prednisolone and fluoxetine can both cause gastric irritation and increase the risk of a gastric bleed. The patient is 65 years old and increased age is an added risk factor. Even if the aspirin is stopped, consideration could be given to the addition of a proton pump inhibitor for gastric protection.
Prednisolone should routinely be prescribed in the morning. Taking corticosteroids later in the day can affect sleep. Mrs Peterson has been taking steroids for over 3 months without bone protection and would therefore be at risk of steroid-induced osteoporosis. Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis advise that at the time of initiation of glucocorticoid treatment in individuals considered high risk, bone-protective therapy should also commence (Bone and Tooth Society of Great Britain, National Osteoporosis Society & Royal College of Physicians, 2002).
The World Health Organisation fracture risk assessment tool, FRAX Õ , gives the 10-year probability of Losartan could be changed to a 100 mg tablet to simplify the dosage and reduce the prescribing cost. The fluoxetine is prescribed in a quantity of 60 capsules which equates to 2 month's supply. The rest of the regular medication is supplied in a monthly quantity.
Reducing the quantity to 30 (to fit with the standard pack size) will more closely align the quantities on the prescription and make ordering easier for the patient. Simvastatin should be taken at night and therefore the dosage on the prescription should state this point.
Paracetamol has been issued 16 times in the last year. Therefore 100 paracetamol tablets are not lasting a month. An assessment should be made of Mrs Peterson's current pain levels and if paracetamol is sufficient the quantity should be increased to allow monthly ordering. After discussing the options and changes with Mrs Peterson the repeats could be updated as follows:
. Paracetamol 500 mg tablets -take two tablets four times a day when required Â 224 tablets . Losartan 100 mg tablets -take one tablet daily Â 28 tablets . Prednisolone 5 mg tablets -take one tablet in the morning Â 28 tablets . Fluoxetine 20 mg capsules -take one capsule once a day Â 30 capsules . Simvastatin 40 mg tablets -take one tablet at night Â 28 tablets . Omeprazole 20 mg capsule -take one capsule once a day Â 28 capsules . Alendronate 70 mg tablets -take one tablet once a week Â 4 tablets . Adcal D3 Õ tablets -take one tablet twice a day Â 56 tablets
Case study 2. Mr Dales.
Mr Dales is a 60-year-old man who has come to see you for a medication review. His medical history includes:
. Hypertension (since 2006) . On statin for primary prevention of cardiovascular disease (since 2011) . Neuralgia in left leg which disturbs his sleep (since 2010) . Eczema (since childhood), mainly affecting the hands . Lower urinary tract symptoms (diagnosed 8 months ago)
Mr Dales' current repeat medication is shown in Fig. 2 . Take a moment to reflect on the medication then continue to read for the outcome of your conversation with Mr Dales.
On asking how he is currently taking his medication, Mr Dales mentions that he cannot take two of the amitriptyline at night as it makes him very groggy the next morning and he has to drive to work so he has only been taking one which seems to help and he is getting a good night's sleep. He usually only needs two co-codamol in the morning and two at teatime although will occasionally need more if he has been doing gardening or something similar. He admits to no longer taking the statin as he has read a lot about them in the paper, especially the one he is on, and he does not like the idea of the side effects that are mentioned.
On asking about the medication that was started for his 'water works', he explains that he had tried them but did not feel they helped him that much. He also noticed he was getting a very dry mouth that he thought may be due to the tablets as he had read the leaflet that came in the box of tablets. He has not found things as bad recently though and is not looking for an alternative.
Mr Dales says he always takes the indapamide and diltiazem as he knows they are important for his blood pressure. He still has the eczema flares especially on his hands and says that the cream in the tube works well and he rarely uses the cream in the tub. He puts the Eumovate Õ on three times a day whenever there is some eczema there. He is also taking glucosamine and chondroitin that he buys online for his joints that he thinks is working well.
Reflect on the medication and information from the patient. How many issues can you identify? Are there any changes to the medication you would consider?
Comment: The amitriptyline dose could be amended to one at night and the quantity reduced to 28 tablets. The dry mouth could have been due to the solifenacin especially if being taken with amitriptyline. As the patient is not requesting further treatment the item can be removed from repeat and an invitation given to return if he wants to review this area further.
There has been a lot in the press recently regarding statins and therefore the patient's concerns about side effects and also the benefits of taking a statin should be discussed. There is Medicines and Healthcare products Regulatory Agency (MHRA) guidance regarding the interaction between . With regards to this interaction, the guidance states that amlodipine and diltiazem 'may increase plasma concentrations of simvastatin, which is associated with an increased risk of myopathy and/or rhabdomyolysis'. (MHRA, 2012) . When prescribing amlodipine or diltiazem in conjunction with simvastatin, the maximum recommended dose of the latter drug is now 20 mg/day. One option, given the patient's particular concerns with simvastatin, would be to offer atorvastatin. Necessary blood tests would need to be scheduled.
Indapamide 2.5 mg tablets are less expensive than the 1.5 mg modified release (M/R) tablets. A switch could be considered in this patient. Diltiazem should always be prescribed by brand. The patient's current brand should be identified and the repeat updated.
The patient's eczema management should be discussed including the role of steroids and emollients, side effects of topical steroids, and frequency of use of topical steroids. The patient has probably been using the steroid cream too frequently and the quantity is too large for the area. The Cetraben Õ has been underused. After discussing the options and changes with Mr Dales the repeats could be updated as follows:
. Amitriptyline 10 mg tablets -take one tablet at night Â 28 tablets . Atorvastatin 10 mg tablets -take one tablet at night Â 28 tablets . Co-codamol 30/500 tablets -take one or two four times a day when required Â 224 tablets . Indapamide 2.5 mg tablets -take one tablet in the morning Â 28 tablets . Slozem Õ 300 mg M/R capsules -take one capsule once a day Â 28 tablets . Cetraben Õ cream -apply regularly as an emollient Â 500 g . Eumovate Õ cream -apply thinly once a day for eczema flares Â 30 g How is a medication review undertaken within your practice? How are patients recalled? How is the review undertaken and how is monitoring arranged? How does the repeat prescribing process work in the practice? What is the role of reception staff (or prescription clerks) in the process? What types of prescription requests need to be referred to a prescriber for consideration? Before asking GP associates in training (AiT) to sign repeat prescriptions, does the practice give an induction to explain medication review procedures and the repeat prescribing process. If not consider putting this in place for the next GP AiT. One of the most important issues to consider when reviewing patients' medications is whether they are taking the medicines as intended which is often termed 'adherence'. Adherence has been defined as 'The extent to which the patient's behaviour matches agreed recommendations from the prescriber' (Horne, Weinman, Barber, Elliott, & Morgan, 2005) . It should be noted that assessing adherence does not cover whether the medication is the correct choice for the patient.
The National Institute for Health and Care Excellence (NICE) has produced a guideline for Medicines Adherence (CG76) which states (NICE, 2009) :
[that] between a third and a half of all medicines prescribed for long term conditions are not taken as recommended. If the prescriptions are appropriate, then this may represent a loss to patients, the healthcare system and society.
Therefore, healthcare professionals should 'recognise that non-adherence is common and that most people are non-adherent sometimes' (NICE, 2009 ). This nonadherence can be in intentional (patients do not want to take the medication) or non-intentional (they have practical problems taking the medication). NICE advises that when non-adherence is identified, a plan should be agreed with the patient and a follow-up date arranged for review (NICE, 2009) . It is important to consider nonadherence before assuming that a medication has been ineffective, or that the dosage needs to be increased.
Case study 3.
A patient has stopped his simvastatin as it has been mentioned in the tabloids again and he is scared he will lose his memory and be put into a home. What type of non-adherence is this? What could be done to improve adherence?
Comment: This scenario is an example of intentional non-adherence. The patient made a conscious decision to stop treatment. Adherence may be improved by a discussion of the benefits and risks of statin therapy and the various statins available. The option of taking an alternative statin that has not been in the news so much may be appealing to the patient. After these discussions, the patient might decide to take a statin again.
Case study 4.
A patient had been taking blood pressure medication for a short time. Her last blood pressure was 'great' according to the nurse so the patient stopped taking it as she thought the problem had resolved. What type of non-adherence is this? What could be done to improve adherence?
Comment: This scenario is an example of non-intentional non-adherence. The patient believed that stopping the medication was the treatment plan. Adherence might be improved by ensuring the patient is aware that hypertension is a long-term condition requiring on-going treatment.
Box 1. Suggestions for effective medication review consultations.
1. Educate patients about the importance of medication review for ensuring their medication remains safe and appropriate 2. Ask reception staff to inform patients when they are booked in for their medication review that, if they wish to discuss any other medical issue, another appointment must be booked 3. Consider proactively inviting patients to medication review just before their repeat medication authorisations become out of date and make the purpose of the consultation clear 4. Allow a longer consultation time for medication review of complicated medication regimens 5. Consider employing a practice pharmacist to undertake medication reviews of patients with complex medication regimens 6. Have contact details for local community pharmacists and build relationships with them. The term medication review is used to cover a variety of different types of review, and examples are shown in Table 1 . In general practices it is possible to do a full clinical review with the patient present, or a clinical notes review without involving the patient. As can be seen from Table 1 the former approach is most comprehensive. Some medication reviews are also available in pharmacies in England and other parts of the UK.
Pharmacy medicines use reviews
A medicines use review (MUR) is a form of medication review performed in community pharmacies in England. The Pharmaceutical Services Negotiating Committee (PSNC) describes an MUR in the following way (PSNC, 2013a):
[it] involves the pharmacist reviewing the patients' use of their medication; ensuring they understand how their medicines should be used and why they have been prescribed; identifying any problems and then, where necessary, providing feedback to the prescriber. MURs are undertaken in the pharmacy and usually without access to the GP clinical record.
The new medicine service
The new medicine service (NMS) is provided by community pharmacies and focuses on patients with long-term conditions that have been prescribed new medicines. At the time of writing, the NMS primarily focuses on five clinical conditions: asthma; chronic obstructive pulmonary disease; type 2 diabetes; antiplatelet/anticoagulant therapy; and hypertension. If a patient is newly prescribed one of the eligible medicines then he or she can be offered the service (which is optional). The pharmacist provides information and advice at initial prescription then follows-up with the patient at 7-14 days and 14-21 days to check adherence, side effects and answer questions (PSNC, 2013b) . The NMS focuses on newly prescribed medication only and is therefore not a full medication review.
Issues to cover in a medication review Table 2 summarises the issues to be covered in a medication review. The process is broken into three parts.
1. An overview, which covers all the information that should be gleaned from the patient 2. A review, which puts the information from the patient and the clinical record together to produce potential action points 3. Action which covers the discussion and agreement of the action points with the patient and completes the administration Table 2 shows the wide range of issues that can be considered as part of medication reviews, and it is a major . Table 2 . Summary of issues to be covered in a medication review.
Step
Issue to be covered Purpose
OVERVIEW

Questions for the patient
How are you getting on with your medication? Do you have any concerns about them or think you have any side effects?
. To identify the patients issues at the start of the consultation . To review possible side effects and determine whether they are possible side effects or a different complaint . To allow the patient to share their thoughts and concerns about their medicines that can be addressed during the review How do you currently take your medication during the day? Prompting the patient to tell you how many tablets and at which time in the day they are taken . To check current usage matches prescribed dose . To check prescription collection data against patients described regimen to help with assessment of adherence . To identify interactions between medications including due to timing of medication, e.g. calcium tablets take with bisphosphonate . To ensure medication is taken at the best time of the day . To assess and document usage of 'as required' medication, e.g. painkillers . To identify if the regimen can be simplified Do you have any difficulty remembering any of your medication or any difficulty taking it?
. To identify who looks after the management of the medication, e.g. spouse, and if a dosette or other compliance aid is being used . To identify and discuss possible solutions to adherence issues or patient preferences ............................................................................................................................................................................................................................ . Table 2 
. Continued
Step Issue to be covered Purpose Do you take any medication from anywhere else including vitamin supplements?
. Consider how you currently undertake medication reviews (you might wish to look at videos of your consultations). Reflect on the extent to which you cover the items highlighted in Table 2 . If you recognise that there are gaps, try to find time in consultations so that you can develop your skills in undertaking thorough and comprehensive medication reviews. Also, develop your skills at addressing key issues when undertaking medication reviews under time pressure in routine consultations.
Key points
. Medication reviews are an important part of the 'repeat prescribing' process: if issues are not addressed during these reviews, inappropriate prescribing may continue for another year . The patient and the GP may approach the concept of a 'medication review appointment' from different perspectives: the GP must use good communication skills to ensure that concordance is reached . During a medication review, the GP should be alert to the possibility of intentional and non-intentional non-adherence to treatment plans; it is necessary to employ a patient-centred approach to prescribing in order to fully address these issues . A comprehensive medication review is multifaceted: it may not be possible to achieve a full review of a patient receiving multiple medications in one 10-minute appointment and may be beneficial to make use of a practice pharmacist in the medication review process . A GP should have good working relationships with local community pharmacists; MUR and NMS reviews are two examples of specific medication reviews that may be provided by community pharmacists Step Issue to be covered Purpose Document any other important information . This will help to ensure the information is available for future prescribing decisions Ensure patients expectations have been met . This will help to ensure patient satisfaction and adherence to the management plan Re-authorise the repeat medication, selecting an appropriate time scale depending on the medication prescribed . This will allow the patient to continue to receive their medicines on repeat prescription for an appropriate amount of time Code the medication review . This helps to clarify that a medication review has been undertaken, and the type of review 
